PAREXEL is a proven and committed partner to drug developers and medical device manufacturers looking to bring innovative new products to market. Our Phase I-IV studies incorporate the full range of services from clinical study design to bioanalytics to peri-approval and post-marketing services, with an emphasis on First in Man and Proof of Concept studies. We have decades of experience, deep expertise, and the global resources required to handle studies – and programs of studies – of any size, anywhere in the world.

Expertise

No matter what your product goal, we have the key to your success – in today's R&D environment, the key to success is maximizing your product value at every milestone and phase of development, no matter what your ultimate product goal. At PAREXEL we offer an integrated, flexible approach with a unique fusion of expertise. Leveraging our global reach and eClinical technologies we strive to efficiently develop your product with the highest quality, safety and compliance in order to add value and help you reach your goal.

Reimbursement

The key to optimal market penetration requires an early and well designed reimbursement strategy that ensures patient access to therapy - Demonstrating product value to patients, physicians and payers is essential with the continuing evolution of evidence-based medicine.

Product value is a key factor in determining whether the new therapy will attain optimal market results.

More

GCPj Awards
PAREXEL Partners with Glenmark to Win the GCPj Award for Most Innovative Patient Recruitment Strategy

PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award from GCPj

Investigator Sign Up

Click here to complete a profile.

 

PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2008/2009

Now Available!
An invaluable resource for executives and managers working within or with the pharmaceutical and biotechnology industries. This 2008/2009 compilation puts real-world data sets and industry insights at your fingertips for presentations, reports, business development efforts, meetings, and critical decision-making analyses.

More Details